Dabrafenib and its potential for the treatment of metastatic melanoma

Alexander M Menzies1
Georgina V Long1,2
Rajmohan Murali3,4
1Melanoma Institute Australia, Sydney, New South Wales, Australia; 2Westmead Institute for Cancer Research and Crown Princess Mary Cancer Centre Westmead, Sydney, New South Wales, Australia; 3Department of Pathology; 4Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Abstract: The purpose of this study is to review the development of BRAF inhibitors, with emphasis on the trials conducted with dabrafenib (GSK2118436) and the evolving role of dabrafenib in treatment for melanoma patients. Fifty percent of cutaneous melanomas have mutations in \textit{BRAF}, resulting in elevated activity of the mitogen-activated protein kinase signaling pathway. Dabrafenib inhibits the mutant BRAF (BRAF\textsuperscript{mut}) protein in melanomas with \textit{BRAF\textsuperscript{V600E}} and \textit{BRAF\textsuperscript{V600K}} genotypes. \textit{BRAF\textsuperscript{V600E}} metastatic melanoma patients who receive dabrafenib treatment exhibit high clinical response rates and compared with dacarbazine chemotherapy, progression-free survival. Efficacy has also been demonstrated in \textit{BRAF\textsuperscript{V600K}} patients and in those with brain metastases. Dabrafenib has a generally mild and manageable toxicity profile. Cutaneous squamous cell carcinomas and pyrexia are the most significant adverse effects. Dabrafenib appears similar to vemurafenib with regard to efficacy but it is associated with less toxicity. It is expected that new combinations of targeted drugs, such as the combination of dabrafenib and trametinib (GSK1120212, a MEK inhibitor), will provide higher response rates and more durable clinical benefit than dabrafenib monotherapy.

Keywords: BRAF mutation, BRAF inhibitor, clinical trial, GSK1120212, GSK2118436, vemurafenib

Introduction
Patients with advanced melanoma have a poor prognosis, with 1-year survival rates as low as 33% and a median overall survival (OS) of approximately 9 months.\textsuperscript{1} Until recently, systemic treatments were largely ineffective. Following the discovery of \textit{BRAF} mutations in melanoma,\textsuperscript{2} there has been rapid development of selective BRAF inhibitors, leading to a major shift in the approach to treating patients with BRAF-mutated (BRAF\textsuperscript{mut}) melanoma. Dabrafenib is a selective BRAF inhibitor characterized by high response rates, a rapid mode of action, little toxicity, and a prolonged progression-free survival (PFS) over chemotherapy.\textsuperscript{3} The authors review the development of BRAF inhibitors, with emphasis on the trials conducted with dabrafenib and its evolving role in treating melanoma patients.

Systemic therapy in the pre-\textit{BRAF} era
Prior to the development of selective BRAF inhibitors and newer immunotherapies,\textsuperscript{4,5} metastatic melanoma was largely refractory to systemic treatment. Dacarbazine (DTIC) was the most commonly used systemic agent. Trials with DTIC and other chemotherapeutic agents (alone or in combination with interferon or interleukin-2) demonstrated response rates below 20%, a median PFS of less than 4 months, and OS.
of less than 9 months.6–11 Interleukin-2 trials reported durable complete responses in less than 10% of patients, but at the cost of significant toxicity.12

**BRAF mutations in melanoma**

**Discovery of BRAF mutations**

A decade ago, a seminal study investigating the mitogen-activated protein kinase (MAPK) pathway identified mutations in the activating segment of the **BRAF** kinase domain.2 Ninety percent of the mutations in **BRAF** involved exon 15 (1799T > A), resulting in the substitution of valine by glutamic acid at residue 600 (initially thought to be 599); this mutation was designated **BRAF<sup>V600E</sup>**. Sixty percent of the melanomas and cell lines investigated in this study harbored the **BRAF<sup>V600E</sup>** mutation.2 The MAPK pathway is a major intracellular signal transduction pathway that is responsible for cellular proliferation, gene expression, differentiation, mitosis, cell survival, and apoptosis (Figure 1). Melanoma cell lines with **BRAF** mutations had elevated kinase activity compared with those with wild-type **BRAF** (**BRAF<sup>wt</sup>**), and they signaled through the MAPK pathway without upstream activation by RAS, indicating that the cells lost their dependence on upstream signaling.2 Furthermore, when **BRAF<sup>V600E</sup>** was ectopically expressed in fibroblast cell lines, it caused hyperstimulation of the MAPK cascade and malignant transformation.2 Subsequent validation studies of melanoma cell lines identified frequent activating mutations in exon 600 of **BRAF**.13

**Effects of mutated BRAF in melanoma**

In vitro data indicate that mutant **BRAF** is oncogenic.2,14 **BRAF** mutations are very common in melanocytic nevi15 and are less prevalent in primary16–21 and metastatic22–24 melanoma. This suggests that the **BRAF** mutation is an early event in neoplastic transformation of melanocytes but is insufficient in itself to lead to malignancy.25 Indeed, the formation of melanocytic nevi appears to result from transformation of melanocytes by **BRAF** mutation, proliferation, and then oncogene (**BRAF**)-induced senescence. Progression from nevus to melanoma requires escape from senescence.26–28 The majority of melanomas are thought to arise de novo from transformed melanocytes without progression through a nevus; in such cases, other genetic alterations (eg, alterations in the p53 and Rb pathways) cooperate with oncogenic **BRAF** mutations to drive malignant transformation.29 Further research is required to fully understand the interplay between **BRAF** mutations and other factors in melanoma development. Furthermore, the role of mutant **BRAF** in melanoma progression from primary to metastatic disease is not clear. Several retrospective studies of stage III

---

Figure 1. Simplified scheme of the mitogen-activated protein kinase (MAPK) (RAS-RAF-MEK-ERK) signaling pathway.

**Notes:** **BRAF** and **NRAS** are the most commonly mutated oncogenes in melanoma. Downstream effectors of the pathway lead to increased survival and proliferation by various mechanisms (eg, increased transcription of genes and regulation of apoptotic proteins). Potential mechanisms of acquired resistance to **BRAF** inhibitor therapy are highlighted in red. **BRAF** inhibition can lead to activation of the MAPK pathway via acquisition of secondary **NRAS** Q61K mutations; **RAF** isoform signal switching (**ARAF** > **BRAF** > **CRAF**); truncation of **BRAF**, resulting in a form that is resistant to the inhibitor; amplification of **BRAF**; MEK1/2 C1215 mutation; and increased expression of COT, a partner kinase.

**Abbreviations:** PDGFRB, platelet-derived growth factor receptor beta; IGF-1R, insulin-like growth factor 1 receptor.
and IV melanoma patients report conflicting results with regard to the associations of \textit{BRAF} mutation status with distant metastasis-free survival and OS.\textsuperscript{22,23,30–33} However, studies with consecutive accrual\textsuperscript{22,23,33} report poorer survival in \textit{BRAF\textsuperscript{mut}} patients than in \textit{BRAF\textsuperscript{wt}} patients.

**BRAF** mutation prevalence, genotypes, and clinicopathologic correlates

\textit{BRAF} mutations occur in approximately 50\% of cutaneous melanomas\textsuperscript{22–24,34} and most commonly occur in exon 15, at codon 600 (V600).\textsuperscript{35} Over 75\% of \textit{BRAF} mutations are characterized by the substitution of valine by glutamic acid at residue 600 (V600E).\textsuperscript{22–24} A less common genotype is V600K, a substitution of valine by lysine. The prevalence of V600K varies by geographic region, ranging from less than 10\% in northern Europe\textsuperscript{15,24,16} to 20\%–30\% in Australia, Texas, and Florida,\textsuperscript{23,34,37,38} likely reflecting differences in ambient ultraviolet (UV) exposure.\textsuperscript{34} Rare V600 mutations include V600R and V600D. The frequency of \textit{BRAF} mutations in melanoma is inversely proportional to patient age,\textsuperscript{14,39} and there are reported associations of \textit{BRAF} mutation status and genotype with anatomic location of primary melanoma, histological subtype, and evidence of cumulative sun damage.\textsuperscript{22,39} Acral and mucosal melanomas have a lower frequency of \textit{BRAF} mutations,\textsuperscript{16,33,40} and uveal melanomas do not harbor \textit{BRAF} mutations.\textsuperscript{41–43}

**Development of \textit{BRAF} inhibitors**

Since the identification of \textit{BRAF} mutations in cutaneous melanomas, much effort has been directed toward the development of pharmacologic agents that inhibit the mutated \textit{BRAF} protein for treatment of melanoma patients. Two types of \textit{BRAF} inhibitors have been developed and tested in advanced melanoma: type 1 \textit{BRAF} inhibitors that bind and inhibit the active conformation of the \textit{BRAF} kinase, and type 2 \textit{BRAF} inhibitors that bind to the inactive conformation of the kinase (Table 1).\textsuperscript{44}

**Nonselective (type 2) \textit{BRAF} inhibitors**

Initial attempts to target \textit{BRAF\textsuperscript{mut}} protein with type 2 inhibitors failed to show clinical efficacy. This was thought to be due to nonselective kinase inhibition, which resulted in significant toxicity at doses well below those required to inhibit the MAPK pathway.

**Sorafenib**

Sorafenib was developed and approved for treatment of kidney and liver cancer prior to the identification of \textit{BRAF} mutations in melanoma. Sorafenib binds to CRAF, \textit{BRAF\textsuperscript{wt}}, and \textit{BRAF\textsuperscript{mut}} proteins, with little selectivity for one isoform over another. It also inhibits other kinases including vascular endothelial growth factor receptor 2 (VEGFR2), vascular endothelial growth factor receptor 3, platelet-derived growth factor, p38 MAPK, FLT, cKIT, FMA, and RET.\textsuperscript{45} Phase II clinical trials in metastatic melanoma patients failed to demonstrate any efficacy of sorafenib as monotherapy, and pharmacodynamic analyses suggested that only partial inhibition of \textit{BRAF} signaling was achieved at the maximum tolerated dose (MTD).\textsuperscript{46–47} Despite this, a phase I/II trial in which sorafenib was given in combination with carboplatin and paclitaxel (CP) reported a high response rate and longer PFS than with standard chemotherapy in metastatic melanoma patients.\textsuperscript{48} Two phase III randomized trials comparing the combination of CP and sorafenib with the combination of CP and placebo failed to show a benefit for the CP and sorafenib arm.\textsuperscript{6,7} To date, no studies have detected any correlation between \textit{BRAF} genotype (mutant versus wild-type) and response to sorafenib, either as a single agent or in combination with chemotherapy.\textsuperscript{48,49}

**RAF265**

RAF265 is another small molecule inhibitor of multiple kinases including \textit{BRAF} (mutant and wild-type), CRAF, VEGFR2, and platelet-derived growth factor receptors,
with greatest potency against \( \text{BRAF}^{V600E} \) and VEGFR2. Unlike sorafenib, RAF265 is a more potent inhibitor of \( \text{BRAF}^{\text{mut}} \) than \( \text{BRAF}^{\text{wt}} \).\(^{50}\) Xenograft studies reported impressive responses in both \( \text{BRAF}^{\text{wt}} \) and \( \text{BRAF}^{\text{mut}} \) tumors,\(^{51}\) but a phase I trial in \( \text{BRAF}^{\text{mut}} \) and \( \text{BRAF}^{\text{wt}} \) metastatic melanoma patients was disappointing, with response rates of 16% and 13%, respectively.\(^{52}\) Further trials of RAF265 monotherapy are not expected.

**Selective (type 1) BRAF inhibitors**

The most promising results in patients with \( \text{BRAF}^{\text{mut}} \) melanoma have been seen with drugs designed to selectively target the mutated and activated form of the BRAF kinase. Type 1 inhibitors bind the active conformation of the kinase, inhibiting BRAF kinase and MAPK activity at doses well below the MTD.\(^{53,54}\) The three drugs in clinical use or undergoing investigation in human clinical trials are (1) vemurafenib, (2) dabrafenib (discussed later in this review), and LGX818 (Table 1). These inhibitors are associated with specific toxicities such as cutaneous squamous cell carcinoma (cuSCC)\(^{55}\) and with the rapid development of resistance.

**Vemurafenib**

The first selective BRAF inhibitor to enter clinical trials was vemurafenib (also designated PLX4032, PLX4720, and RG7204). Vemurafenib was developed alongside a companion real-time polymerase chain reaction-based assay (cobas\textsuperscript{®} 4800 BRAF V600 Mutation Test; Roche Molecular Diagnostics, Inc, Pleasanton, CA) designed to detect the \( \text{BRAF}^{V600E} \) mutation. This test is highly sensitive and specific for the \( V600E \) BRAF mutation but is less so for other \( V600 \) BRAF mutations (eg, \( V600K, V600R, V600D, \) or the \( 1799_\text{G} \rightarrow \text{A} 1800_\text{T} \) mutation).\(^{36-59}\)

Preclinical evidence demonstrated vemurafenib activity in \( \text{BRAF}^{V600E} \) melanoma but not in \( \text{BRAF}^{\text{wt}} \) melanoma. Clinical trials began in patients with solid tumors and then focused on those with \( \text{ RAF } 4800 \)-positive metastatic melanoma, demonstrating high activity, a rapid mode of action, and significant clinical benefit.\(^{60}\) Initial results from the phase III trial were reported in 2011,\(^{51}\) and recently more mature data has been presented.\(^{61}\) When used as a first-line agent in \( \text{BRAF}^{V600E} \) metastatic melanoma, vemurafenib had a Response Evaluation Criteria in Solid Tumors (RECIST) response rate\(^{63}\) of 53%, a median PFS of 6.9 months, and a median OS of 13.6 months, compared with conventional DTIC chemotherapy’s response rate of 8%, median PFS of 1.6 months, and median OS of 10 months.\(^{61,62}\) A phase I study in patients with brain metastases showed intracranial activity,\(^{54}\) and a phase II study is currently under way (NCT01378975). In phase II and III trials, vemurafenib was active in a small number of patients retrospectively identified with \( \text{BRAF}^{V600E} \) tumors (\( n=20,4\% \) of the total study population).\(^{6,60}\) The response rate was less than that in patients with \( \text{BRAF}^{V600E} \) tumors, and no survival data were presented regarding these patients. There is anecdotal evidence for vemurafenib activity in tumors with other \( \text{BRAF} \) mutations (including \( \text{BRAF}^{V600R} \) and \( \text{BRAF}^{V600D} \)), and a trial to formally investigate activity in non-V600E \( \text{BRAF}^{\text{mut}} \) melanoma is under way (NCT01586195).

Vemurafenib has received worldwide regulatory approval for treatment of patients with \( \text{V600} \) \( \text{BRAF}^{\text{mut}} \) metastatic melanoma, although in the United States and Brazil the approval is restricted to patients with \( \text{BRAF}^{V600E} \) melanoma. The V600 approval is based upon the inclusion of all \( \text{BRAF}^{\text{mut}} \) patients in the clinical trials (as determined by the cobas 4800 test), despite the fact that over 95% of patients in these trials were \( \text{BRAF}^{V600E} \) patients and despite there being little evidence of efficacy outside this genotype.

**LGX818**

LGX818 is a type 1 BRAF inhibitor under investigation in phase I clinical trials, both as a single agent (NCT01436656) and in combination with other targeted therapies (NCT01543698).

**Dabrafenib**

**Drug design and preclinical activity**

Dabrafenib (GSK2118436) is a reversible and potent adenosine triphosphate-competitive inhibitor that selectively inhibits the \( \text{BRAF}^{V600E} \) kinase. The drug concentration required for 50% inhibition of \( \text{BRAF}^{V600E} \) kinase activity (IC50) is five times lower than that for \( \text{BRAF}^{\text{wt}} \) or CRAF.\(^{65}\) Preclinical data demonstrated that dabrafenib inhibits the MAPK pathway in \( \text{BRAF}^{V600E} \) melanoma cells, leading to decreased proliferation and regression in xenograft mouse models.\(^{65}\)

**Clinical trials**

Dabrafenib trial results are summarized in Table 2.

**Phase I trial (BREAK-1)**

Clinical trials of dabrafenib began in 2009. Initial results of the phase I trial were presented in 2010,\(^{66,67}\) and the final results were reported in 2012.\(^{54}\) This trial included patients with solid tumors and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Initial inclusion criteria did not require the presence of \( \text{BRAF} \) mutation, but this was
Table 2 Summary of dabrafenib trial results

<table>
<thead>
<tr>
<th>Variable</th>
<th>BREAK-1&lt;sup&gt;a&lt;/sup&gt;</th>
<th>BREAK-2&lt;sup&gt;b&lt;/sup&gt;</th>
<th>BREAK-3&lt;sup&gt;c&lt;/sup&gt;</th>
<th>BREAK-MB&lt;sup&gt;d&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>156&lt;sup&gt;a&lt;/sup&gt;</td>
<td>92</td>
<td>187&lt;sup&gt;b&lt;/sup&gt;</td>
<td>172</td>
</tr>
<tr>
<td>BRAF&lt;sup&gt;V600E&lt;/sup&gt;</td>
<td>131</td>
<td>76</td>
<td>187</td>
<td>139</td>
</tr>
<tr>
<td>BRAF&lt;sup&gt;V600K&lt;/sup&gt;</td>
<td>18</td>
<td>16</td>
<td>0</td>
<td>33</td>
</tr>
<tr>
<td>Non-V600 BRAF&lt;sup&gt;mut&lt;/sup&gt;</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Efficacy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RR (%)</td>
<td>56 (V600E)</td>
<td>60 (V600E)</td>
<td>53</td>
<td>31–36 (V600E)&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td>PFS (months)</td>
<td>22 (V600K)</td>
<td>13 (V600K)</td>
<td>5.1</td>
<td>7–22 (V600K)&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td>OS (months)</td>
<td>5.5 (V600E)</td>
<td>6.2 (V600E)</td>
<td>N/A</td>
<td>3.7 (V600E)</td>
</tr>
<tr>
<td>Toxicity (%)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>7.1–7.6 (V600E)</td>
</tr>
<tr>
<td>cuSCC/KA</td>
<td>11</td>
<td>9</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Pyrexia*</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>6</td>
</tr>
</tbody>
</table>

Notes: <sup>a</sup> Number of melanoma patients treated; <sup>b</sup> number of dabrafenib patients treated; <sup>c</sup> investigator-assessed intracranial RR; <sup>d</sup> grade 3 pyrexia or pyrexia defined as a serious adverse event.

Abbreviations: RR, response rate; PFS, progression-free survival; OS, overall survival; N/A, not available; cuSCC, cutaneous squamous cell carcinoma; KA, cutaneous keratoacanthoma.

mandated early during the escalation phases because of a lack of activity in three patients with BRAF<sup>mut</sup> tumors. The primary aim of the study was to establish safety, tolerability, and the recommended phase 2 dose (RP2D) of dabrafenib. Secondary objectives were to determine pharmacokinetic and pharmacodynamic profiles and tumor response. The trial began with dose titration from 12 mg daily until the RP2D of 150 mg twice a day (BID) was defined. After establishment of the dosage, three expanded cohorts were added: (1) those with metastatic melanoma, (2) those with asymptomatic untreated brain metastases (≥3 mm size), and (3) those with nonmelanoma solid tumors.

Of the 156 melanoma patients enrolled in the study, three were BRAF<sup>wt</sup>, 131 were BRAF<sup>V600E</sup>, 18 were BRAF<sup>V600K</sup>, two were BRAF<sup>K601E</sup>, one was BRAF<sup>V600K,K601E</sup>, and one had an uncharacterized BRAF mutation. The most common grade 2 or higher toxicities were cuSCC or keratoacanthoma (KA) (11%), fatigue (8%), and pyrexia (6%). Palmoplantar hyperkeratoses and actinic keratoses were common (26% and 10%, respectively) but mild. Dose reductions occurred in 7% of patients, and 76% of patients had no drug-related adverse events of greater severity than grade 2. MTD was not reached at doses of up to 300 mg BID; however, a minority of patients developed dose-limiting effects at 300 mg BID (two of ten patients) and 200 mg BID (three of 20 patients). A RP2D of 150 mg BID was selected, since patients on 200 mg BID showed minimal increase in drug exposure (area under the curve) with no increase in the proportion of patients with RECIST response, metabolic response assessed by positron emission tomography, or MAPK inhibition (measured by phospho-ERK expression on biopsy) and with the development of some dose-limiting events.

Of the 36 BRAF<sup>V600E</sup> melanoma patients treated at RP2D, 25 (69%) had a complete or partial response, and 18 (50%) had a confirmed response. Of the 27 BRAF<sup>V600K</sup> melanoma patients, 21 (78%) had complete or partial responses, and 15 (56%) had confirmed responses. Of the 18 BRAF<sup>V600K</sup> patients receiving any dose of dabrafenib, seven (39%) showed responses, and these responses were confirmed in four (22%) patients. The median PFS was similar (approximately 5.5 months) in BRAF<sup>V600E</sup> and BRAF<sup>V600K</sup> patients. Nine (90%) of the ten patients with BRAF<sup>V600</sup> melanoma and previously untreated brain metastases showed a decrease in the size of their brain tumors, with four patients (40%) achieving complete responses. No responses were seen in patients with BRAF<sup>K601E</sup> or BRAF<sup>V600K,K601E</sup> mutations.

Responses were also seen in BRAF<sup>V600E</sup> nonmelanoma tumors, including papillary thyroid cancer (n = 9) and non-small cell lung cancer (n = 1). Stable disease was seen in gastrointestinal stromal tumor (n = 1) and ovarian cancer (n = 1). Of the nine BRAF<sup>V600E</sup> colorectal cancer patients with known BRAF status, one (11%) had a partial response and seven (78%) had stable disease.

In summary, the phase I study showed dabrafenib to be safe and tolerable, showed that dabrafenib demonstrated activity in BRAF<sup>V600E</sup> and BRAF<sup>V600K</sup> melanoma, and showed that dabrafenib was the first drug to show activity in melanoma metastases in the brain.
Phase II trial (BREAK-2)
The single-arm, open-label, phase II trial included patients with BRAF\textsuperscript{V600E} or BRAF\textsuperscript{V600K} metastatic melanoma without prior therapy with BRAF or MEK inhibitors.\textsuperscript{10} Patients with current or prior brain metastases were excluded. The primary objective was to determine the response rate in BRAF\textsuperscript{V600E} patients, with secondary objectives including response rate in BRAF\textsuperscript{V600K} patients, duration of response, PFS, OS, safety, and tolerability.

In 92 enrolled patients (76 BRAF\textsuperscript{V600E}, 16 BRAF\textsuperscript{V600K}), dabrafenib was dosed at 150 mg BID. Most patients (63%) had American Joint Committee on Cancer stage M1c disease, and 84% had received prior therapy for metastatic disease. Adverse events were common but rarely led to dose reduction (14%) or discontinuation (1%). Most frequent (ranging from 15% to 33%) toxicities of any grade were arthralgia, hyperkeratosis, pyrexia, fatigue, headache, nausea, and skin papillomas. Serious adverse events occurred in 27% of patients and included cuSCCs (9%), basal-cell carcinomas (4%), and pyrexia (3%).

Response rates were impressive in BRAF\textsuperscript{V600E} patients (7% complete response, 53% partial response) but less so in BRAF\textsuperscript{V600K} patients (0% complete response, 13% partial response). A minority of patients (16% BRAF\textsuperscript{V600E}, 31% BRAF\textsuperscript{V600K}) appeared to derive no benefit from treatment and had progressive disease at first assessment. The median PFS was longer (27 weeks in BRAF\textsuperscript{V600E} patients, 20 weeks in BRAF\textsuperscript{V600K} patients) than that reported for standard chemotherapies.

Phase III trial (BREAK-3)
The phase III trial recruited patients with stage IV or unresectable stage IIIC BRAF\textsuperscript{V600E} melanoma, with no prior therapy for advanced disease (apart from interleukin-2 in one patient), and an ECOG performance status of 0 or 1.\textsuperscript{3} Patients with a history of brain metastases required demonstration of stability for 3 months after local treatment (surgery, stereotactic radiotherapy). The trial was conducted in a 3:1 randomized, open-label design, with patients receiving either dabrafenib 150 mg BID or DTIC (1000 mg/m\textsuperscript{2} every 3 weeks), with crossover to dabrafenib upon disease progression in those receiving DTIC. The primary end point was investigator-assessed PFS, with secondary end points including PFS, as assessed by an independent review committee (IRC); OS; objective response rate by revised RECIST guidelines (version 1.1),\textsuperscript{11} as determined by an investigator and an IRC; PFS after crossover from DTIC to dabrafenib; duration of response; quality of life; safety; and tolerability.

Initial results were reported in mid–2012.\textsuperscript{3} Two hundred and fifty BRAF\textsuperscript{V600E} patients were enrolled, 187 in the dabrafenib arm and 63 in the DTIC arm. The two treatment groups were well balanced. Most patients receiving dabrafenib had an ECOG performance status of 0 (66%), American Joint Committee on Cancer stage M1c disease (66%), and a normal serum lactate dehydrogenase (LDH) level (64%). Response, outcome, and toxicity data were presented as of data cutoff on December 19, 2011, at which time 57% of patients in the dabrafenib group were still receiving treatment, with a median follow-up of 4.9 months.

Investigator-assessed estimated median PFS in the dabrafenib group was 5.1 months, compared with 2.1 months in the DTIC group, and the hazard ratio (HR) for progression was 0.30 (95% confidence interval [CI], 0.18–0.51; \(P < 0.0001\)). PFS as assessed by an IRC was 6.7 months for dabrafenib and 2.9 months for DTIC (HR, 0.35; 95% CI, 0.20–0.61). The improved PFS with dabrafenib was seen in all subgroups (ECOG performance statuses 0 and 1; normal and elevated LDH levels; age < 65 years and ≥65 years; male and female; disease stages IIIC, M1a, M1b, and M1c). OS data were not mature, and mortality rates were only 11% and 14% in the dabrafenib and DTIC arms, respectively. Twenty-two percent of DTIC patients were still receiving treatment, 44% having crossed over to dabrafenib after disease progression. Confirmed responses by an IRC were seen in 50% of dabrafenib patients (3% complete, 47% partial), and 6% of DTIC patients (2% complete, 4% partial). The median time to response in the dabrafenib group was 6.3 weeks (the time of first tumor assessment). The estimated median duration of response was 5.5 months. Twenty-eight patients in the DTIC group progressed and then crossed over to dabrafenib by the time of trial analysis; of these patients, 13 (46%) achieved subsequent partial responses.

Toxicities were similar to those seen in the early-phase trials, the most common being cutaneous manifestations (hyperkeratosis, papillomas, palmar-plantar erythrodysesthesia), pyrexia, fatigue, headache, and arthralgia. Twelve (6%) of 187 patients had cuSCCs/KAs, three patients (2%) developed new primary melanomas, and phototoxicity was rare (3%). Dose reductions occurred in 28% of patients, and 3% of patients permanently discontinued therapy because of toxicity.

OS data are expected to be similar to the data seen with vemurafenib,\textsuperscript{3,62} in that the improved PFS will parallel improved OS. The difference in OS between the treatment arms will no doubt be diminished because of crossover in the DTIC group, but nevertheless it should remain, as in the vemurafenib trial.
Phase II brain metastases trial (BREAK-MB)

Following the impressive results seen in the ten patients enrolled in the phase I trial with active brain metastases, a dedicated phase II study was conducted to further examine the effect of dabrafenib in those with untreated, or previously treated but relapsed, brain metastases. This trial enrolled patients with \( \text{BRAF}^{V600E} \) melanoma, no prior MAPK therapy (BRAF or MEK inhibitors), asymptomatic brain metastases, ECOG performance status of 0–1, and up to two prior lines of systemic therapy for metastatic disease. Patients were allowed corticosteroids if they were receiving a stable or decreasing dose over 3 weeks prior to enrollment, and at least one brain metastasis needed to be between 0.5 and 4 cm in size to be a measurable target lesion. The presence of leptomeningeal disease excluded patients from the study. The primary end point was the investigator-assessed overall intracranial response rate (OIRR) in \( \text{BRAF}^{V600E} \) patients, and secondary end points were, in \( \text{BRAF}^{V600K} \) patients, the OIRR and, in all patients, the overall response rate, degree of intracranial and overall response, PFS, and OS.

One hundred and seventy-two patients were enrolled in two cohorts: (1) those without prior local treatment for brain metastases (n = 89) and (2) those with brain metastases previously treated with local therapy (surgery, stereotactic radiosurgery, and/or whole brain radiotherapy) but with subsequent intracranial progression (n = 83). The two cohorts were unbalanced with regard to ECOG performance status, the number of target brain metastases, and prior therapies received, and were therefore not directly comparable. However, most patients in both cohorts had an ECOG performance status of 0, an elevated serum LDH level, fewer than four target brain metastases, and had received previous chemo- or immuno-therapy.

Dabrafenib was well tolerated, and the toxicity was similar to that seen in the aforementioned studies, with the exception of intracranial hemorrhage, which occurred in 6% of patients. Hemorrhage occurred in both cohorts, in both responding and progressive lesions; it did not appear higher than the background rate, \(^{71,72} \) and it was thought to be related to the patient population and their intracranial disease rather than to the drug.

Responses were seen in both cohorts, and in both \( \text{BRAF}^{V600E} \) and \( \text{BRAF}^{V600K} \) genotypes. In \( \text{BRAF}^{V600E} \) melanoma patients, the investigator-assessed OIRRs in untreated patients and in previously treated patients were 39% and 31%, respectively, while the overall response rates were 38% and 31%, respectively. The intracranial disease control rate (defined as complete + partial response + stable disease) was 80%–90%.

In \( \text{BRAF}^{V600E} \) patients in both cohorts, the median PFS was 16 weeks and the median OS was 31–33 weeks. In untreated and previously treated \( \text{BRAF}^{V600K} \) melanoma patients (n = 33), OIRRs were 7% and 22%, respectively, and disease control rates were 33% and 50%, respectively. The median PFS ranged from 8 to 16 weeks, and the median OS ranged from 16 to 22 weeks, the difference between the cohorts being most likely due to the small numbers involved. No data were available regarding the causes of disease progression, but the causes may be inferred from the results of a single institution study of 20 patients that reported that progression occurred in the brain alone in 30% of patients, in the brain and extracranially in 40%, and extracranially alone (with ongoing intracranial control) in 30%.\(^{73} \)

The results of this trial were impressive when compared with studies of systemic agents, which report response rates of less than 10%, PFS of less than 2 months, and OS of 3–5 months.\(^{11,74-76} \) The findings suggested that dabrafenib may be an effective adjunct for treatment of brain metastases (alongside surgery and radiotherapy), and that it warrants consideration as first-line therapy in patients with brain metastases, particularly if the brain metastases are multiple or concurrent with advanced extracranial disease.

Differences between dabrafenib and vemurafenib

Dabrafenib and vemurafenib are both selective type I BRAF inhibitors with proven efficacy in \( \text{BRAF}^{V600E} \) metastatic melanoma. They share many attributes, including clinical activity and class-defined toxicity; however, differences between the drugs exist in regard to RAF kinase inhibition, toxicities, and prospective evidence for activity in non-\( V600E \) \( \text{BRAF} \) melanoma and in brain metastases.

Selective inhibition of RAF kinases and MTD

Vemurafenib and dabrafenib are more selective for \( \text{BRAF}^{\text{mut}} \) than other kinases, including \( \text{BRAF}^{\text{wt}} \). Vemurafenib has similar potency for inhibition of CRAF (IC50 48 nM) and \( \text{BRAF}^{V600E} \) (IC50 31 nM), while dabrafenib has less potency for inhibition of CRAF (IC50 5 nM versus 0.6 nM for \( \text{BRAF}^{V600E} \)).\(^{53,66} \) The ratios of IC50 for CRAF and \( \text{BRAF}^{V600E} \) compared with that for \( \text{BRAF}^{\text{wt}} \) are 0.5 and 0.3, respectively, for vemurafenib\(^{53} \) and 0.4 and 0.05, respectively, for dabrafenib,\(^{66} \) indicating that dabrafenib is a more selective inhibitor of \( \text{BRAF}^{V600E} \) than vemurafenib. Furthermore, dabrafenib has similar potency for inhibition of \( \text{BRAF}^{V600E} \) and \( \text{BRAF}^{V600K} \).\(^{54} \) Dabrafenib did not reach MTD in the phase I trial,\(^{54} \) and its therapeutic dose...
was based on a minimum increase in drug exposure, clinical response, and MAPK inhibition at the next higher dose level (200 mg BID). Vemurafenib reached MTD (960 mg BID) in its phase I trial, with unacceptable toxicities developing in four of six patients (grade 3 rash and arthralgia) at the next higher dose level (1120 mg BID).

Efficacy in non-V600E BRAF melanoma patients

Vemurafenib has only been studied prospectively in \textit{BRAF}^{V600E} patients, since the companion diagnostic test used to define study entry (cobas 4800) is highly sensitive and specific for the \textit{BRAF}^{V600E} mutation. Definitive conclusions regarding response rates, PFS, and OS in vemurafenib-treated \textit{BRAF}^{V600E} melanoma cannot be derived because of the small number of patients in the phase II and III trials that were retrospectively characterized as \textit{BRAF}^{V600E}. A clinical trial to evaluate vemurafenib activity in patients with non-V600E 
exon 15 \textit{BRAF} mutations is under way (NCT01586195). Dabrafenib was prospectively tested in non-V600E \textit{BRAF} genotypes in the phase I and II trials, and there is good evidence for its activity in \textit{BRAF}^{V600E} melanoma.

Efficacy in \textit{BRAF}^{V600E} melanoma patients

It is difficult to compare the relative clinical efficacy of dabrafenib and vemurafenib in \textit{BRAF}^{V600E} melanoma patients, as no head-to-head trials have been conducted. Furthermore, mature outcome data regarding PFS and OS are only available at this time for vemurafenib. From the available data, it appears that the trials of each drug included patients with similar disease characteristics. Based on this, rough comparisons can be made, and these suggest the drugs share similar response rates (approximately 50%) in \textit{BRAF}^{V600E} patients. The phase III trials of dabrafenib and vemurafenib trials both reported similar PFS results at early time points (5.1 and 5.3 months, respectively). The median PFS with vemurafenib is 6.9 months, and mature PFS data from dabrafenib-treated patients are yet to be reported.

Intracranial activity

Dabrafenib has proven intracranial activity, and phase I and II trial data support its clinical efficacy in \textit{BRAF}^{V600E} and \textit{BRAF}^{V600K} patients with brain metastases. Vemurafenib is expected to exhibit similar intracranial activity; however, at present, results are only available from a small phase I study of \textit{BRAF}^{V600E} patients. A larger phase II study in cobas-positive (\textit{BRAF}^{V600E}) melanoma patients is ongoing (NCT01378975).

Toxicity

Trials of dabrafenib and vemurafenib show differences in the incidences of toxicities (Tables 3 and 4). Cutaneous toxicities such as rash, hyperkeratosis, cuSCC, and KA occur with both drugs but have been reported to occur at a lesser degree with dabrafenib. Of note, cuSCCs occur in 19% of patients with vemurafenib and in only 5% of patients with dabrafenib. Other toxicities such as arthralgia and fatigue also appear to occur at a higher rate and grade with vemurafenib. Drug-specific toxicities include photosensitivity and hepatitis with vemurafenib and pyrexia with dabrafenib. The need for dose reduction or interruption due to toxicity was approximately 30%–40% for both drugs, with only a minimal number of patients treated with either drug, permanently discontinuing therapy because of toxicity.

The higher incidence of class-like toxicities seen with vemurafenib than with dabrafenib is likely to be due to several factors: differences in drug dose (vemurafenib is dosed at one level below MTD, while the MTD for dabrafenib is unknown); RAF inhibitor potency (\textit{BRAF}\text{mut} and CRAF); histopathologic assessment of cutaneous lesions (central review in the phase I and II studies of vemurafenib only); classification and reporting of toxicity; and different geographic populations enrolled in the studies (eg, differences in UV exposure affecting inherent cuSCC risk). Analysis of the mechanisms of cutaneous toxicities (notably, cuSCC) suggest that in \textit{BRAF}\text{mut} cells, BRAF inhibitors cause formation of RAF dimers that lead to signaling through CRAF, particularly in those with an upstream mutation such as \textit{RAS}. Studies have shown frequent mutations in \textit{HRAS}, and to a lesser extent \textit{NRAS}, in benign and malignant (cuSCCs) proliferative lesions resected from patients on BRAF inhibitors.

Table 3 Comparative toxicities of vemurafenib and dabrafenib

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Vemurafenib</th>
<th>Dabrafenib</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperkeratosis</td>
<td>Present</td>
<td>51%</td>
</tr>
<tr>
<td>Palmoplantar hyperkeratosis/erythrodysesthesia</td>
<td>10%&lt;sup&gt;a&lt;/sup&gt;</td>
<td>21%</td>
</tr>
<tr>
<td>cuSCC/KA</td>
<td>30%</td>
<td>7%</td>
</tr>
<tr>
<td>Rash</td>
<td>41%</td>
<td>22%&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>56%</td>
<td>16%</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>NR</td>
<td>15%</td>
</tr>
<tr>
<td>Photosensitivity</td>
<td>41%</td>
<td>3%</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>26%</td>
<td>NR</td>
</tr>
<tr>
<td>Dose reduction or interruption</td>
<td>38%</td>
<td>28%&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Discontinuation</td>
<td>7%</td>
<td>3%</td>
</tr>
</tbody>
</table>

Notes: <sup>a</sup>Data from the phase II vemurafenib trial<sup>60</sup>; data from the phase II dabrafenib trial<sup>64</sup> only dose reduction data presented. Toxicity data are from phase III clinical trials. <sup>3,61,62,122</sup> Hyperkeratosis and rash have been poorly defined or classified in trials, making comparisons difficult.

Abbreviations: cuSCC, cutaneous squamous cell carcinoma; KA, cutaneous keratoacanthoma; NR, not reported.
Table 4 Outcome measures and grade 3/4 toxicities with BRAF and MEK inhibitors

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Vemurafenib&lt;sup&gt;11,42&lt;/sup&gt;</th>
<th>Dabrafenib&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Trametinib&lt;sup&gt;39,49&lt;/sup&gt;</th>
<th>CombiDT (150/2)&lt;sup&gt;144&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>RR (%)</td>
<td>57</td>
<td>53</td>
<td>22</td>
<td>76</td>
</tr>
<tr>
<td>DCR (%)</td>
<td>97</td>
<td>95</td>
<td>78</td>
<td>100</td>
</tr>
<tr>
<td>PFS (months)</td>
<td>6.9</td>
<td>5.1</td>
<td>4.8</td>
<td>9.4</td>
</tr>
<tr>
<td>OS (months)</td>
<td>13.6</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Toxicity (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cuSCC</td>
<td>19</td>
<td>5</td>
<td>0</td>
<td>5&lt;sup&gt;+&lt;/sup&gt;</td>
</tr>
<tr>
<td>KA</td>
<td>10</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Hyperkeratosis</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>9</td>
<td>0</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Other</td>
<td>10, hepatitis</td>
<td>12, hypertension</td>
<td>7, cardiac</td>
<td>1, ocular</td>
</tr>
</tbody>
</table>

Note: cuSCC and KA combined; only vemurafenib has mature outcome data at this stage.

Abbreviations: CombiDT, combined dabrafenib and trametinib; 150/2, dose of dabrafenib 150 mg BID and trametinib 2 mg daily; RR, response rate (complete + partial response); DCR, disease control rate (complete + partial response + stable disease); PFS, progression-free survival; OS, overall survival; NA, not assessable; cuSCC, cutaneous squamous cell carcinoma; KA, cutaneous keratoacanthoma.

Dabrafenib has proven activity in patients with metastatic melanoma, including those with brain metastases. The most common toxicities are cutaneous and mild, rarely leading to discontinuation. Compared with previous systemic therapies for metastatic melanoma, dabrafenib is highly effective, with high response rates and an improved survival; however, acquired resistance remains the greatest limitation. Combinations of dabrafenib with other agents, including immunotherapies and other targeted agents, hold great promise for improved treatment of melanoma patients.

Pyrexia is a specific toxicity seen with dabrafenib that may respond to steroids. The mechanisms underlying dabrafenib-associated pyrexia are poorly understood and require further investigation.

Photosensitivity occurs with vemurafenib, it may develop despite minimal UV exposure, and it is often a cause of significant morbidity. Across the phase I–III trials with vemurafenib, photosensitivity occurred in 40%–50% of patients (all grades), and 3% were grade 3. The only dabrafenib trial reporting photosensitive reactions was the phase III study, in which 3% of patients had low-grade toxicity, with no grade 3 events. Photosensitivity was not reported in the phase I and II trials of dabrafenib and is therefore considered to be a vemurafenib-specific toxicity.

Limitations of dabrafenib and future directions for treatment of patients with metastatic melanoma

Dabrafenib has proven activity in patients with BRAF<sup>V600E</sup> and BRAF<sup>V600K</sup> metastatic melanoma, including those with brain metastases. The most common toxicities are cutaneous and mild, rarely leading to discontinuation. Compared with previous systemic therapies for metastatic melanoma, dabrafenib

Variable response and resistance to BRAF inhibitors

There is a broad spectrum of response to dabrafenib and vemurafenib therapy. A minority of patients (3%–5%) demonstrate no overall RECIST response (progressive disease at first assessment), while a few (3%–5%) show complete responses with long-term remission and are possibly cured. However, the vast majority of patients have rapid, incomplete, and heterogeneous early treatment responses (shrinkage of tumors and decline in tumor metabolism assessed by positron emission tomography), with subsequent overall disease progression at variable time points during treatment. This phenomenon occurs as a result of both primary and acquired resistance, and inter- and intratumoral heterogeneity—features that present major challenges for drug development.

To date, there are no biomarkers that accurately predict clinical outcomes (response, PFS, and OS). Studies assessing baseline pretreatment tissue and tissue taken early during treatment (approximately 2 weeks after starting therapy) that have examined many markers of MAPK pathway activity and other signaling pathways have shown little correlation with clinical outcome. The best current indicator of outcome is the BRAF genotype, with BRAF<sup>V600E</sup> melanoma patients consistently performing better than patients with non-V600E BRAF<sup>V600E</sup> melanomas.
A small number of studies have been performed in pretreatment tissues and cell lines to assess for mechanisms of primary resistance. These suggest that amplification of the CCND1 gene (encoding cyclin D1), and stromal expression of hepatocyte growth factor, may play a role in conferring primary resistance to BRAF inhibitor treatment. Most attention, however, has been focused on understanding the specific mechanisms behind the development of acquired resistance to BRAF inhibitors. Biopsies of progressing tumors from patients, when compared with corresponding pretreatment samples, usually demonstrate reactivation of the MAPK pathway. This has been shown to occur because of acquired aberrations including amplification of BRAF, RAF isoform switching, new mutations in NRAS and MEK, and increased expression of COT, a partner kinase (Figure 1). A minority of cases do not demonstrate MAPK reactivation but do show increased signaling through other pathways (such as the PI3K pathway); these appear to be a result of increased expression of growth factor receptors such as insulin-like growth factor 1 receptor and platelet-derived growth factor receptor beta. To date, it appears that no single mechanism predominates. However, changes to the drug-binding site in the BRAF protein (a common mechanism of acquired resistance with other targeted therapies) have not been reported.

Other targeted agents
MEK inhibitors have also been studied in BRAFmut melanoma. They were designed to inhibit MAPK signaling at a level downstream of BRAF. The development of MEK inhibitors began prior to that of BRAF inhibitors, and MEK inhibitors showed limited effect in initial trials in melanoma patients without unknown BRAF status. Impressive results have been obtained in more recent trials that were conducted in BRAFmut melanoma patients.

Trametinib (GSK1120212) is the best-studied MEK inhibitor in BRAFmut melanoma. A phase I trial demonstrated significant activity in BRAFmut melanoma, with little activity in BRAFwt patients, while a phase II study in BRAFV600EK patients with or without prior BRAF inhibitor treatment demonstrated no response when given after BRAF inhibitor failure. Initial reports from the recent first-line phase III trial show a response rate of 22% and a median PFS of 4.8 months (Table 4), compared with an 8% response and 1.4 months’ PFS in the chemotherapy (DTIC or paclitaxel) arm. OS data were immature, but the HR for progression or death was 0.54 (95% CI, 0.32–0.92; \( P = 0.01 \)). The 6-month OS rate in the intention-to-treat population was 81% in the trametinib group and 67% in the chemotherapy group, despite 47% of patients in the chemotherapy group crossing over to trametinib upon disease progression. Toxicities included MEK inhibitor class-like effects such as rash (including acneiform rash), hypertension, diarrhea, edema, transient mild cardiac dysfunction, rare ocular toxicity (chorioretinopathy), and creatine kinase elevation. Most toxicities were mild and did not require drug discontinuation.

The results of the trial suggest that trametinib was not as effective as dabrafenib (or vemurafenib) therapy but still showed impressive single-agent activity. Monotherapy with trametinib rather than dabrafenib would only appear prudent for those who could not tolerate dabrafenib because of toxicity.

Combination dabrafenib and trametinib
An effective strategy to build upon the successes seen with dabrafenib and trametinib monotherapies has been to combine these agents (CombiDT), with the goal of further improving response rates and delaying resistance. As both drugs target the MAPK pathway, combined blockade may circumvent or delay acquired resistance because of reactivation of the MAPK pathway. Combining the two drugs may also reduce the toxicities of each drug when given individually (especially cutaneous toxicity from dabrafenib).

The initial phase I/II trial involved BRAFV600EK metastatic melanoma patients across multiple cohorts. These cohorts included a drug–drug interaction cohort (Part A), dose escalation and expansion cohorts (Part B), and a large randomized cohort (Part C). In Part C, patients were randomized 1:1:1 to CombiDT at a dose of dabrafenib 150 mg BID and trametinib 1 mg daily, CombiDT at a dose of dabrafenib 150 mg BID and trametinib 2 mg daily (150/2), or dabrafenib monotherapy (150 mg BID). Analysis of data from the randomized phase II (Part C) trial in BRAF/MEK inhibitor-naïve melanoma patients reported a response rate of 76% in those receiving CombiDT at the 150/2 dose, which was significantly higher than that in patients receiving dabrafenib monotherapy (54%; \( P = 0.026 \)). More important, the median PFS of 9.4 months in those receiving CombiDT at the 150/2 dose was significantly longer than that in the dabrafenib monotherapy arm (5.8 months; HR, 0.39; \( P < 0.0001 \)). These results are better than those reported in the previous phase III dabrafenib and trametinib monotherapy trials (Table 4). Additionally, in the Part B expansion cohort of patients with prior disease progression during BRAF inhibitor treatment, an impressive 19% response rate was seen with CombiDT therapy.
Toxicities with this combination were generally mild. Notably, cutaneous toxicities such as hyperkeratosis, cuSCC, KA, and rash were greatly reduced, and there appeared to be a reduction in diarrhea and hypertension (trametinib-related toxicities) compared with single-agent trametinib trials. The most common toxicity was fever, occurring in approximately 70% of patients (5% grade 3/4) of those patients receiving CombiDT at the 150/2 dose – much more frequent than with dabrafenib monotherapy.3,106 The mechanisms underlying the pyrexia remain incompletely understood, but pyrexia generally occurs early, is often an isolated episode, can be managed with brief dose interruption and corticosteroid prophylaxis (in recurrent cases), and does not require dose reduction.108 Furthermore, pyrexia does not appear to be related to disease burden or treatment response.108

Two phase III trials of CombiDT are under way, comparing CombiDT at the 150/2 dose with dabrafenib (NCT01584648) and vemurafenib (NCT01597908) monotherapies. The results of these studies may lead to replacement of BRAF inhibitor monotherapy by combination BRAF and MEK inhibitor therapy as the first-line treatment for BRAF\textsuperscript{mut} melanoma.

Other combinations
Further combination treatments are being proposed as an increased understanding of the factors involved in tumor response and resistance develops, as well as the development of new drugs that target pathways in the melanoma cell outside the MAPK axis.

Immunotherapies, which directly manipulate T-cell activation in the hope of improving antitumor immunity, have recently emerged as an important form of treatment for metastatic melanoma. The first agent with proven activity, ipilimumab, is an anti-CTLA-4 antibody that binds to and inhibits the CTLA-4 T-cell receptor, resulting in sustained but nonspecific T-cell activation. Two phase III clinical trials have now been completed in the first,109 and second-line settings,110 with reported response rates of 11%–15%, a median PFS of 2.8 months, and a median OS of 10–11 months. One- and two-year survival was approximately 47% and 26%, respectively – a 10% increase over the control arms. Activity has also been demonstrated in patients with small and asymptomatic brain metastases.111 Early-phase trials of other immune agents, including anti-CD-112,113 and anti-PD-L1 antibodies,114 have shown these immune agents appear to be more active and less toxic than ipilimumab.

Combining BRAF inhibitors with immunotherapy would appear to be safe and effective, given differences in their modes of action and toxicity profiles. Translational evidence in support of this approach is also robust, with evidence that BRAF inhibition leads to increased expression of melanoma differentiation antigens and an influx of tumor-infiltrating lymphocytes.88,115 A trial of vemurafenib and ipilimumab has commenced (NCT01400451), and it is expected that dabrafenib will be combined with immunotherapy in the future.

Combinations of drugs targeting other cell signaling pathways (eg, BRAF inhibitors plus PI3K inhibitors), based on discoveries of BRAF inhibitor resistance mechanisms, have entered clinical trials.

Adjuvant therapy
Given the impressive activity of dabrafenib and vemurafenib in BRAF\textsuperscript{mut} metastatic melanoma, it is expected that they may have an important role to play in adjuvant therapy of early-stage melanoma. At present, there is little therapy available for patients with early-stage melanoma. The only approved treatment, interferon, is highly toxic, requires a prolonged duration of treatment, and has little impact on OS.116,117 A trial of adjuvant ipilimumab versus placebo has completed recruitment and results are expected in 2013 (NCT00636168). The adjuvant trial of vemurafenib versus placebo in resected stage IIC/III melanoma (NCT01667419) has commenced, and a trial of CombiDT versus placebo in resected stage III melanoma (NCT01682083) will open soon.

Conclusion
Fifty percent of cutaneous melanomas have mutations in BRAF. These mutations result in highly elevated activity of the MAPK signaling pathway, which mediates cell growth and survival. Dabrafenib effectively inhibits BRAF\textsuperscript{mut} kinase, thereby inhibiting MAPK signaling in BRAF\textsuperscript{mut} melanoma. In patients with BRAF\textsuperscript{mut} metastatic melanoma, dabrafenib confers high response rates and an improved PFS over chemotherapy, with a mild, manageable toxicity profile; however, the duration of benefit is usually brief because of the development of acquired resistance. It is expected that new combination therapies targeting multiple components of cell signaling, such as CombiDT, will provide higher response rates and more durable clinical benefit than dabrafenib monotherapy.

Summary points
- BRAF mutations occur in 50% of melanomas; 70%–90% are V600E and 10%–30% are V600K.
- Selective (type 1) BRAF inhibitors (dabrafenib, vemurafenib) target mutant BRAF kinase and inhibit the MAPK pathway.
Both drugs provide high response rates and rapid modes of action, but both are limited by the rapid development of acquired resistance.

Both dabrafenib and vemurafenib are effective in treating \( BRAF^{V600E} \) melanoma patients, with prospective evidence of dabrafenib activity in \( BRAF^{V600K} \) melanoma and in those with brain metastases.

Both drugs have similar toxicity profiles; dabrafenib appears to have less cutaneous and hepatic toxicity than vemurafenib, but is associated with pyrexia.

Emerging combination strategies, such as the CombiDT, are designed to improve response and delay resistance.

**Disclosure**

The authors acknowledge the following support and funding: A Menzies received travel support from Roche and Glaxo-SmithKline; G Long received institutional research support from Roche and travel support from Roche and Bristol-Myers Squibb. G Long is a consultant advisor to Roche, Glaxo-SmithKline, Bristol-Myers Squibb, and Amgen; R Murali reports no conflicts of interest in this work.

**References**


